封面：开发用于检测趋化因子受体 CCR6 和 CXCR1 细胞内配体的 NanoBRET 检测平台（ChemMedChem 20/2024）

IF 3.6 4区医学 Q2 CHEMISTRY, MEDICINAL

ChemMedChem Pub Date : 2024-10-17 DOI:10.1002/cmdc.202482001

Max E. Huber, Silas L. Wurnig, Dr. Aurélien F. A. Moumbock, Lara Toy, Prof. Dr. Evi Kostenis, Ana Alonso Bartolomé, Dr. Martyna Szpakowska, Dr. Andy Chevigné, Prof. Dr. Stefan Günther, Prof. Dr. Finn K. Hansen, Prof. Dr. Matthias Schiedel

{"title":"封面：开发用于检测趋化因子受体 CCR6 和 CXCR1 细胞内配体的 NanoBRET 检测平台（ChemMedChem 20/2024）","authors":"Max E. Huber, Silas L. Wurnig, Dr. Aurélien F. A. Moumbock, Lara Toy, Prof. Dr. Evi Kostenis, Ana Alonso Bartolomé, Dr. Martyna Szpakowska, Dr. Andy Chevigné, Prof. Dr. Stefan Günther, Prof. Dr. Finn K. Hansen, Prof. Dr. Matthias Schiedel","doi":"10.1002/cmdc.202482001","DOIUrl":null,"url":null,"abstract":"<p>The newly developed NanoBRET assay platform allows the detection of intracellular ligand binding to the chemokine receptors CCR6 and CXCR1, enables equilibrium as well as kinetic binding studies in a cell-free and cellular environment, provides further evidence for the existence of a druggable IABS at CCR6 and CXCR1, and allows mapping of CCR6 and CXCR1 ligands to distinct binding sites of these receptors. More details can be found in article 10.1002/cmdc.202400284 by Finn K. Hansen, Matthias Schiedel, and co-workers.<figure>\n <div><picture>\n <source></source></picture><p></p>\n </div>\n </figure>\n </p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":"19 20","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cmdc.202482001","citationCount":"0","resultStr":"{\"title\":\"Front Cover: Development of a NanoBRET Assay Platform to Detect Intracellular Ligands for the Chemokine Receptors CCR6 and CXCR1 (ChemMedChem 20/2024)\",\"authors\":\"Max E. Huber, Silas L. Wurnig, Dr. Aurélien F. A. Moumbock, Lara Toy, Prof. Dr. Evi Kostenis, Ana Alonso Bartolomé, Dr. Martyna Szpakowska, Dr. Andy Chevigné, Prof. Dr. Stefan Günther, Prof. Dr. Finn K. Hansen, Prof. Dr. Matthias Schiedel\",\"doi\":\"10.1002/cmdc.202482001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>The newly developed NanoBRET assay platform allows the detection of intracellular ligand binding to the chemokine receptors CCR6 and CXCR1, enables equilibrium as well as kinetic binding studies in a cell-free and cellular environment, provides further evidence for the existence of a druggable IABS at CCR6 and CXCR1, and allows mapping of CCR6 and CXCR1 ligands to distinct binding sites of these receptors. More details can be found in article 10.1002/cmdc.202400284 by Finn K. Hansen, Matthias Schiedel, and co-workers.<figure>\\n <div><picture>\\n <source></source></picture><p></p>\\n </div>\\n </figure>\\n </p>\",\"PeriodicalId\":147,\"journal\":{\"name\":\"ChemMedChem\",\"volume\":\"19 20\",\"pages\":\"\"},\"PeriodicalIF\":3.6000,\"publicationDate\":\"2024-10-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cmdc.202482001\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ChemMedChem\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cmdc.202482001\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ChemMedChem","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cmdc.202482001","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

摘要

新开发的 NanoBRET 检测平台可以检测细胞内配体与趋化因子受体 CCR6 和 CXCR1 的结合，在无细胞和细胞环境中进行平衡和动力学结合研究，进一步证明 CCR6 和 CXCR1 存在可药用的 IABS，并可将 CCR6 和 CXCR1 配体映射到这些受体的不同结合位点。更多详情请见 Finn K. Hansen、Matthias Schiedel 及合作者撰写的文章 10.1002/cmdc.202400284。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Front Cover: Development of a NanoBRET Assay Platform to Detect Intracellular Ligands for the Chemokine Receptors CCR6 and CXCR1 (ChemMedChem 20/2024)

查看原文本刊更多论文

Front Cover: Development of a NanoBRET Assay Platform to Detect Intracellular Ligands for the Chemokine Receptors CCR6 and CXCR1 (ChemMedChem 20/2024)

The newly developed NanoBRET assay platform allows the detection of intracellular ligand binding to the chemokine receptors CCR6 and CXCR1, enables equilibrium as well as kinetic binding studies in a cell-free and cellular environment, provides further evidence for the existence of a druggable IABS at CCR6 and CXCR1, and allows mapping of CCR6 and CXCR1 ligands to distinct binding sites of these receptors. More details can be found in article 10.1002/cmdc.202400284 by Finn K. Hansen, Matthias Schiedel, and co-workers.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

ChemMedChem 医学-药学

CiteScore

6.70

自引率

2.90%

发文量

280

审稿时长

1 months

期刊介绍： Quality research. Outstanding publications. With an impact factor of 3.124 (2019), ChemMedChem is a top journal for research at the interface of chemistry, biology and medicine. It is published on behalf of Chemistry Europe, an association of 16 European chemical societies. ChemMedChem publishes primary as well as critical secondary and tertiary information from authors across and for the world. Its mission is to integrate the wide and flourishing field of medicinal and pharmaceutical sciences, ranging from drug design and discovery to drug development and delivery, from molecular modeling to combinatorial chemistry, from target validation to lead generation and ADMET studies. ChemMedChem typically covers topics on small molecules, therapeutic macromolecules, peptides, peptidomimetics, and aptamers, protein-drug conjugates, nucleic acid therapies, and beginning 2017, nanomedicine, particularly 1) targeted nanodelivery, 2) theranostic nanoparticles, and 3) nanodrugs. Contents ChemMedChem publishes an attractive mixture of: Full Papers and Communications Reviews and Minireviews Patent Reviews Highlights and Concepts Book and Multimedia Reviews.